New advances in antiangiogenic combination therapeutic strategies for advanced non-small cell lung cancer

Purpose Tumor growth relies on the sufficient blood supply and continuously requires new blood vessels to maintain, which lead to vascular abnormalities (Folkman, N Engl J Med 285:1182–1186, 1971). Antiangiogenic therapy has emerged with the goal of normalizing vasculature and tumor microenvironment...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cancer research and clinical oncology 2020-03, Vol.146 (3), p.631-645
Main Authors: Qiang, Huiping, Chang, Qing, Xu, Jianlin, Qian, Jialin, Zhang, Yanwei, Lei, Yuqiong, Han, Baohui, Chu, Tianqing
Format: Article
Language:English
Subjects:
Angiogenesis Inhibitors - therapeutic use
Antiangiogenic agents
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Bevacizumab
Biomarkers
Blood vessels
Cancer Research
Carcinoma, Non-Small-Cell Lung - drug therapy
Chemotherapy
Clinical trials
Hematology
Humans
Immunotherapy
Internal Medicine
Lung cancer
Lung Neoplasms - drug therapy
Medical Oncology - methods
Medical Oncology - trends
Medicine
Medicine & Public Health
Monoclonal antibodies
Non-small cell lung carcinoma
Oncology
Protein-tyrosine kinase
Review – Clinical Oncology
Small cell lung carcinoma
Targeted cancer therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose Tumor growth relies on the sufficient blood supply and continuously requires new blood vessels to maintain, which lead to vascular abnormalities (Folkman, N Engl J Med 285:1182–1186, 1971). Antiangiogenic therapy has emerged with the goal of normalizing vasculature and tumor microenvironment (TME). Some antiangiogenic therapies combined with chemotherapy, targeted therapy or immunotherapy have been approved for clinical application. In this review, we summarize the recent advances of antiangiogenic combination therapeutic strategies in advanced NSCLC. Methods References of this review are searched through PubMed and EMBASE and the abstracts of cancer conferences. The ClinicalTrials.gov database was used for relative trials. Results Based on different mechanisms, antiangiogenic agents can be divided into monoclonal antibodies (mAbs), which mainly include bevacizumab and ramucirumab, and multi-target antiangiogenic tyrosine kinase inhibitors (TKIs) which include sunitinib, sorafenib, nintedanib, apatinib, anlotinib, fruquintinib, etc. In recent years, a number of large clinical studies have shown that antiangiogenic agents have conferred a significant overall survival (OS) benefit to patients with advanced non-small cell lung cancer (NSCLC). More and more evidences confirm that the combination of antiangiogenic agents with chemotherapy, targeted therapy and immunotherapy can improve the effect and prolong the survival of NSCLC patients. However, many problems about the application of antiangiogenic agents on advanced NSCLC patients still need to be explored. For example, the combination therapy of multi-target antiangiogenic agents is just beginning, and the biomarkers are not clear. Conclusions Antiangiogenic agents can achieve therapeutic benefit in advanced NSCLC patients and the combination of chemotherapy, targeted therapy or immunotherapy can lead to synergistic effect. However, exploring the best combination therapy and efficacy-related biomarkers needs further study.
ISSN:0171-5216
1432-1335
DOI:10.1007/s00432-020-03129-6